Improving Sexual and Reproductive Health Communication for Adolescent and Young Adult Oncology Patients

Trial statusNot yet recruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age15-25
SponsorConnecticut Children's Medical Center

About this trial

The goal of this clinical trial is to learn if ReSPECT, which includes a pre-visit checklist for patients to complete and an informational website, can work well in practice to help adolescent and young adult oncology patients communicate with their clinicians about sexual and reproductive health (SRH). SRH includes topics such as how cancer may impact puberty and development, best methods for contraception during cancer treatment, fertility risk and fertility preservation strategies, and dating/relationships during and after cancer. The study will also help researchers better understand how to best measure the impact of ReSPECT on improving SRH communication for future testing of ReSPECT.

The main questions the study aims to answer are:

How well does ReSPECT work in practice? Do patients and clinicians like ReSPECT, and do they find it helpful? What are the best ways to test ReSPECT and measure whether it works?

Participants will:

Use ReSPECT to support a conversation about SRH during an outpatient oncology clinic appointment Complete surveys before and after using ReSPECT Provide feedback on their experience using ReSPECT in a short interview

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Age 15-25 years old

Has a cancer diagnosis

≥2 months from diagnosis/initiation of therapy, whichever occurred later

Currently on cancer-directed therapy

Disqualifiers

Not able to provide informed consent/assent

Insufficient cognitive functioning to complete study measures, as determined by a member of the patient's primary oncology team

Exceeds primary oncologist's participant limit (3 patients/clinician)

Trial design

Design model

Single group

Treatments tested in this trial

  • ReSPECT

    Behavioral

    ReSPECT is a multi-modal digital intervention that integrates a pre-visit questionnaire and targeted patient and clinician education to support SRH communication in the outpatient oncology clinic setting. For the purposes of this study it will be used in conjunction with a single regularly scheduled clinic visit.

Treatment groups

30 Participants
are divided into 1 treatment group
Group A: ReSPECT Intervention ArmExperimental treatment 1 intervention

Trial outcomes

Primary outcomes

1

Feasibility

Feasibility will be evaluated based on intervention enrollment (% of participants that complete consent/assent that complete all enrollment procedures, including the T1 survey), completion (% of enrolled AYAs completing the PVQ and the T2 survey) and retention (% of enrolled AYAs and clinicians completing all steps through the T3 survey). ReSPECT will be deemed feasible if intervention enrollment, completion and retention rates are ≥80%, ≥80%, and ≥70%, respectively

Time frame
From enrollment until T3 survey completion (8 weeks post-visit)
2

Acceptability

Acceptability will include usability. Acceptability measures will be modeled on the Theoretical Framework of Acceptability, and include the rating of seven statements on a 5-point Likert scale (Strongly Disagree to Strongly Agree). Acceptability will be defined as ≥70% of AYA and clinician participants rating the intervention acceptable (average score 4 or higher). Usability will be assessed by the Intervention Usability Scale (IUS), a 10-item survey that measures responses to statements on a 5-point Likert scale ("strongly disagree" to "strongly agree". Scores are converted and averaged to produce a total score from 0 to 100, with a score of 70 or higher set as the threshold for satisfactory usability. ReSPECT will be deemed usable if ≥70% of AYA and clinician participants rate the intervention usable (average score 70 or higher).

Time frame
From enrollment until T2 survey completion (within 48 hours post-visit)
3

Perceived Usefulness

Perceived usefulness will be evaluated in post-encounter semi-structured qualitative interviews with AYAs and clinicians. Sample questions include, "Was the SRH conversation helpful? Why or why not?" and, "What is the most useful part of ReSPECT? What is the least useful?". Additional questions will also cover perceived potential impact of ReSPECT improving SRH, barriers encountered using ReSPECT, and opportunities for improvement.

Time frame
Timepoint 2
4

SRH Communication

Participants will be asked if the sexual health topic(s) selected on the PVQ were discussed during the clinic visit (yes/no) and about who initiated the conversation (AYA patient/clinician). They will also complete a brief survey listing each of the 7 sexual health subtopics and indicate whether or not the topic was discussed, who initiated the topic conversation, and (for patients) whether they asked their clinician any questions about the specific topic. AYA patient participants will also be asked if there were topics/information not addressed or inadequately addressed during the visit along with whether or not additional people were in the room during the conversation. Data to be collected were adapted from an instrument used for similar sexual health communication research in adult cancer populations

Time frame
From enrollment until T3 survey completion (8 weeks post-visit)

Secondary outcomes

1

Self-Efficacy

Self-efficacy will be measured by a two-item scale assessing AYA and clinician confidence (1) initiating and (2) participating in discussions about SRH topics. Responses range from 0 (not at all confident) to 10 (extremely confident) for each topic.

Time frame
From enrollment until T3 survey completion (8 weeks post-visit)
2

Outcome Expectancies

The Outcome Expectancy Scale is a 6-item scale assessing AYA's perception of the extent to which outcomes may result from discussing SRH topics with their oncology clinician. Potential outcomes include answering question(s), finding a solution to a problem, giving peace of mind, helping play an active role in one's health care, improving SRH, and helping make decisions. For each item, responses range from 0 (not at all) to 10 (very much).

Time frame
From enrollment until T3 survey completion (8 weeks post-visit)
3

Decisional Confidence (Decision Making)

Decisional confidence will be assessed by a single-item survey measure to assess whether ReSPECT helped AYAs make an informed decision about a SRH question/concern. Participants will be asked to respond with yes/no, then to describe why/why not.

Time frame
From enrollment until T3 survey completion (8 weeks post-visit)
4

Distress/Bother

The Level of Bother Scale is a single-item scale assessing the extent to which participants have been bothered by specific SRH concerns in the last month. Responses are scored on a 4-point Likert scale, with higher scores indicating greater levels of bother.

Time frame
From enrollment until T3 survey completion (8 weeks post-visit)

Other outcomes

1

Health Literacy

The Chew Health Literacy Screen is a validated 3-item questionnaire designed to identify individuals with inadequate health literacy. Items are scored on a 5-point Likert scale, with higher scores indicating greater health literacy

Time frame
Timepoint 1
2

Depression and Anxiety

The Hospital Anxiety and Depression Scale (HADS) is a 14-item scale with subscales for anxiety and depression (7 items each). Items were validated in the outpatient medical clinic setting and do not assess somatic complaints. Each item is rated on a 4-point scale ranging from 0 (absence) to 3 (extreme presence), with higher scores indicating greater levels of anxiety and depression

Time frame
From enrollment until T3 survey completion (8 weeks post-visit)
3

Sexual Health

The COG Sexual Health Task Force Sexual Health Assessment is an 8-item survey designed to assess SH outcomes among AYAs with cancer and includes sexual history, sexual function, body image, and romantic relationships. Question types include Likert scales, yes/no questions, and multiple-response checklists.

Time frame
From enrollment until T3 survey completion (8 weeks post-visit)

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

Connecticut Children's Medical Center

Lead sponsor

National Cancer Institute (NCI)

Collaborator

This trial is not recruiting at the moment. You can still explore other options: